Sluggish Growth in Bioprosthetic Valve Sales Due to the Widespread Adoption of TAVI
First written in FY2018-Q1. 7 of 12 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the stagnation in bioprosthetic valve sales growth due to the spread of TAVI. - FY2021-Q3RestatedAnnual report
「Sales of prosthetic heart valve products ended in May 2019.」
The Company has reconfirmed the discontinuation of prosthetic heart valve product sales, while the stagnation in sales growth of existing products due to the spread of TAVI remains a theme from the period after the products were discontinued. - FY2021-Q2RestatedAnnual report
「Sales of prosthetic heart valve products ended in May 2019.」
The Company has reconfirmed that the handling of prosthetic heart valve products ended in May 2019. - FY2020-Q1DroppedAnnual report
「Sales of prosthetic heart valve products were discontinued following the expiration of the exclusive distribution agreement with the supplier at the end of May 2019.」
The handling of prosthetic heart valve products ended upon expiration of the agreement, and the business-related statement about bioprosthetic valve sales struggling to grow due to the spread of TAVI does not appear in this filing. - FY2019RestatedAnnual report
「Revenue from products related to prosthetic heart valves declined from the previous fiscal year against the backdrop of the growing adoption of minimally invasive catheter-based treatment.」
The decline in revenue from prosthetic heart valve products due to the growing adoption of minimally invasive catheter-based treatment has continued. - FY2019-Q3RestatedAnnual report
「In the prosthetic heart valve business, sales volume of the bioprosthetic valve CROWN PRT, handled by the Company and requiring open-heart surgery, declined from the same period of the previous year as minimally invasive catheter-based treatment became more widely adopted.」
The decline in CROWN PRT sales volume has continued against the backdrop of the growing adoption of minimally invasive catheter-based treatment. - FY2019-Q2RestatedAnnual report
「In the prosthetic heart valve business, sales volume of the bioprosthetic valve CROWN PRT, handled by the Company, declined from the same period of the previous year as TAVI (transcatheter aortic valve implantation) products handled by competitors became more widely adopted.」
The decline in CROWN PRT sales volume due to the spread of TAVI has continued. - FY2019-Q1RestatedAnnual report
「In the prosthetic heart valve business, sales volume of the bioprosthetic valve CROWN PRT, handled by the Company, declined from the same period of the previous year, reflecting the spread of TAVI (transcatheter aortic valve implantation).」
The spread of TAVI continued to weigh on bioprosthetic valve sales, and CROWN PRT sales volume declined year on year. - FY2018WorsenedAnnual report
「In prosthetic heart valves, revenue from the company's bioprosthetic and mechanical valves declined slightly from the previous fiscal year as minimally invasive treatments such as TAVI became more widespread.」
Against the backdrop of the spread of TAVI and other treatments, bioprosthetic and mechanical valve sales shifted from the slight year-on-year increase reported in the previous quarter to a slight decline from the previous fiscal year. - FY2018-Q3MitigatedAnnual report
「In prosthetic heart valves, revenue from the company's bioprosthetic valves and prosthetic rings increased only slightly from the same period of the previous year as minimally invasive treatments such as TAVI became more widespread.」
Despite the spread of TAVI and other treatments, revenue from bioprosthetic valves and prosthetic rings increased slightly year on year, indicating a modest recovery in sales performance from the slight decline reported in the previous quarter. - FY2018-Q2WorsenedAnnual report
「In prosthetic heart valves, sales volumes of the company's bioprosthetic valves declined slightly from the previous fiscal year as minimally invasive treatments such as TAVI became more widespread in the treatment of valvular heart disease.」
Against the backdrop of the spread of TAVI, bioprosthetic valve sales deteriorated from the previous quarter's level of the same period of the previous year to a slight decline from the previous fiscal year. - FY2018-Q1First statedAnnual report
「In prosthetic heart valves, sales of the company's CROWN PRT bioprosthetic valve remained at the level of the same period of the previous year as TAVI became more widespread in the treatment of valvular heart disease.」
As TAVI became more widespread, sales of the CROWN PRT bioprosthetic valve remained at the level of the same period of the previous year.